Krzysztof Pawlaczyk
Biographic Data
| ID | 7872313 |
|---|---|
| NAME | Krzysztof Pawlaczyk |
| GIVEN NAMES | Krzysztof |
| FAMILY NAME | Pawlaczyk |
| SIGNATURE | PAWLACZYK K |
| AFFILIATIONS | Poznan University of Medical Sciences |
| ORCID | 0000-0001-6237-0814 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2021 |
| H-INDEX | 0 |
Considerations for Home-Based Treatment of Fabry Disease in Poland during the Covid-19 Pandemic and Beyond
Current therapy for Anderson-Fabry disease in Poland includes hospital or clinic-based intravenous enzyme replacement therapy with recombinant agalsidase alpha or beta, or oral pharmacological chaperone therapy with migalastat. Some countries around the world offer such treatment to patients in the comfort of their own homes. The 2020-2021 COVID-19 pandemic has pushed global healthcare providers to evolve their services so as to minimize the risk…
No prominent works on this page.
Considerations for Home-Based Treatment of Fabry Disease in Poland during the Covid-19 Pandemic and Beyond
Current therapy for Anderson-Fabry disease in Poland includes hospital or clinic-based intravenous enzyme replacement therapy with recombinant agalsidase alpha or beta, or oral pharmacological chaperone therapy with migalastat. Some countries around the world offer such treatment to patients in the comfort of their own homes. The 2020-2021 COVID-19 pandemic has pushed global healthcare providers to evolve their services so as to minimize the risk…
Bioinformatics (1 work) · Carbohydrate Chemistry and Synthesis (1 work) · Coronavirus disease 2019 (COVID-19 (1 work) · Disease (1 work) · Enzyme replacement therapy (1 work) · Fabry disease (1 work) · Health care (1 work) · Infectious disease (medical specialty (1 work) · Intensive care medicine (1 work) · Internal Medicine (1 work)